BML Capital Management LLC Takes $327,000 Position in Kezar Life Sciences, Inc. (NASDAQ:KZR)

BML Capital Management LLC purchased a new stake in Kezar Life Sciences, Inc. (NASDAQ:KZR) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 48,668 shares of the company’s stock, valued at approximately $327,000. Kezar Life Sciences makes up 0.2% of BML Capital Management LLC’s holdings, making the stock its 20th largest position.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. XTX Topco Ltd raised its position in shares of Kezar Life Sciences by 256.1% in the third quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock valued at $40,000 after buying an additional 37,504 shares in the last quarter. Peapod Lane Capital LLC acquired a new stake in shares of Kezar Life Sciences in the fourth quarter valued at approximately $833,000. Geode Capital Management LLC raised its position in shares of Kezar Life Sciences by 15.0% in the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after buying an additional 81,678 shares in the last quarter. Ikarian Capital LLC raised its position in shares of Kezar Life Sciences by 23.0% in the third quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock valued at $827,000 after buying an additional 200,000 shares in the last quarter. Finally, Stonepine Capital Management LLC raised its position in shares of Kezar Life Sciences by 42.0% in the third quarter. Stonepine Capital Management LLC now owns 1,491,305 shares of the company’s stock valued at $1,153,000 after buying an additional 440,853 shares in the last quarter. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

KZR has been the subject of a number of analyst reports. William Blair reiterated an “outperform” rating on shares of Kezar Life Sciences in a research report on Friday, February 28th. HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a research report on Monday, December 2nd. Finally, Wells Fargo & Company lowered their price objective on shares of Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Thursday, December 19th.

Kezar Life Sciences Stock Up 3.8 %

Shares of KZR opened at $6.08 on Friday. Kezar Life Sciences, Inc. has a one year low of $5.20 and a one year high of $10.40. The company has a market cap of $44.36 million, a P/E ratio of -0.46 and a beta of 0.49. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 7.65. The firm has a 50 day simple moving average of $6.29 and a two-hundred day simple moving average of $6.72.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.